Primary progressive multiple sclerosis

This phase 3 trial tests whether the oral drug orelabrutinib can slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 705 adults aged 18–60 with PPMS will receive either orelabrutinib or a placebo for up to 5 years. The study measures ti…

This early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…

This phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 m…

This study looks at whether people with multiple sclerosis can safely switch from their current anti-CD20 therapy to a new under-the-skin version of ocrelizumab. About 100 participants will be followed for up to 48 weeks to see if brain lesions stay stable and if they are satisfi…

This early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…

This early study tests a new treatment called S103 (BCMA-CAR T cells) in 9 adults with progressive or hard-to-treat multiple sclerosis (MS). The main goal is to see if the treatment is safe and to find the best dose. Researchers will also look for early signs that it might help c…

This study tests whether clemastine fumarate, a common allergy medicine, can help repair the protective coating around nerves (myelin) in people with multiple sclerosis. About 74 adults with relapsing-remitting MS will receive either the drug or a placebo, and advanced MRI scans …

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…

This early-stage study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The main goal is to find a safe dose and check for side effects in…

This early-stage trial tests a cell therapy called TRX319 in 39 adults with progressive multiple sclerosis (MS). The goal is to see if it is safe and to find the best dose. Participants receive TRX319 infusions, sometimes after a chemotherapy drug called bendamustine, and are fol…

This early-stage trial tests a personalized cell therapy called KYV-101 for people with progressive forms of multiple sclerosis (MS) that are not responding to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy certain immune cells …

This early-phase trial is testing whether repeated injections of stem cells from donated fat tissue are safe for people with primary progressive multiple sclerosis (MS). Ten participants will receive the cells directly into the spinal canal. The main goal is to check for serious …

This study tests a home-based balance training program for people with multiple sclerosis (MS). The program combines stepping games, strength, and thinking tasks. Researchers will compare it to a simple stretching routine in 75 adults with MS to see if it improves physical functi…

This study looks at how multiple sclerosis affects the autonomic nervous system, which controls automatic body functions like heart rate and sweating. Researchers will use skin biopsies and heart tests to measure nerve damage in 60 people with relapsing-remitting or primary progr…

This study looks at how sleep issues contribute to tiredness and thinking problems in people with multiple sclerosis (MS). About 382 MS patients and a control group without MS will have overnight sleep tests, thinking assessments, and questionnaires. The goal is to better underst…

This study looks at how the brain uses sugar (glucose) in people with multiple sclerosis (MS) compared to healthy volunteers. Researchers will use a special PET scan to measure brain activity and compare it with MRI scans and blood tests. The goal is to find better ways to diagno…

This study aims to understand how brain connections (synapses) are lost in progressive multiple sclerosis (MS). Researchers will use a new type of PET scan to measure synaptic density in 30 people with progressive MS, relapsing-remitting MS, and healthy volunteers. The goal is to…

This study is collecting health data, smartphone app measurements, and biological samples from 100 people with multiple sclerosis. Researchers aim to find new biomarkers and digital tools to better understand how MS progresses and when it changes form. The goal is to improve moni…

This study looks at whether short selfie videos taken on a phone can accurately measure walking and speech changes in people with multiple sclerosis (MS). About 300 adults with MS will record 5 videos every 3 months for a year and also attend some in-person visits. The goal is to…